Research letter
Well-designed and properly executed randomized controlled trials (RCTs) provide the strongest evidence on the effects of interventions. However, eligibility criteria and the willingness to participate may result in differences between participants and non-participants.
When participants differ considerably from non-participants, the participants will not be representative for the domain of study. As a consequence, the results of the trial may not be generalizable to that domain of patients. (1) However, this will only be the case if the characteristics (e.g. age) in which the groups differ, modify the effect of the intervention (e.g. that the effect is larger or smaller in older or younger patients). (2) Such 'effect modifiers' may differ per intervention. Selectivity of participants of RCTs in general is well known but representativeness of heart failure (HF) patients in e-health trials is lacking. Insight in representativeness in e-health is pivotal as the number of trials in this area increases. They might even be more sensitive to selectivity then device and drug trials in HF, as they require active participation and possible technical 'savviness'. We aimed to compare characteristics of participants with non-participants in the e-Vita HF study that evaluates e-health in patients with HF and to compare characteristics of e-Vita HF participants with participants of previous ehealth randomized studies in HF.
We used data from the Dutch multicenter e-Vita HF study, a randomized trial on the effectiveness of two e-health tools in patients with HF. Table 1 shows characteristics of participants and non-participants. Participants were younger (mean age 66.7 vs. 73.4 years), more often male (75% vs. 58%), and had fewer comorbidities. After adjustment for age anemia and angina pectoris were no longer significantly different, and SES became significantly higher in participants. From the Cochrane review we retrieved information on participants (data on non-participants was not presented) of 18 studies evaluating telemonitoring interventions, published between 2001 and 2014. The mean age was 68 years (range 54 to 78 years), 73% (range 35 to 85%) were men, 30% (4 to 43%) with diabetes and 43% (15 to 67%) with hypertension. ‡MI=myocardial infarction, ¥renal insufficiency = patients < 65 years, creatinine clearance < 45 ml/min; ≥ 65 years, creatinine clearance < 30 ml/min, ¶P-value calculated with chi-square test and T-test, §P-value calculated with multiple linear or (ordinal) logistic regression analysis.
The e-Vita HF trial participants were similar to the participants of previous e-health studies. This is the first study on representativeness of HF participants in an e-health RCT. In line with RCTs evaluating pharmaceutical interventions in chronic HF patients, participants in the e-Vita HF study were younger, more often male and had fewer comorbidities than nonparticipants. (7) HF. This requires detailed characteristics of non-participants to be reported in future trials and individual patient data analysis to assess subgroup effects (identify effect modifiers).
In conclusion, participants differ from non-participants in HF e-health studies.
Differences between participating and non-participating HF patients should be taken into account in the interpretation of research findings and e-health trials should report patient's characteristics of non-participants.
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